[4-(4-trifluoromethyl-phenoxy)-phenyl]-methanol | 933786-79-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [4-(4-trifluoromethyl-phenoxy)-phenyl]-methanol
• 英文别名: (4-{[4-(trifluoromethyl)phenyl]oxy}phenyl)methanol；(4-(4-(Trifluoromethyl)phenoxy)phenyl)methanol；[4-[4-(trifluoromethyl)phenoxy]phenyl]methanol
• CAS: 933786-79-9
• 化学式: C₁₄H₁₁F₃O₂
• 分子量: 268.235
• InChiKey: DFIYQZIHZLMLHU-UHFFFAOYSA-N

物化性质

• 沸点：
  339.1±42.0 °C(Predicted)
• 密度：
  1.293±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  [4-(4-trifluoromethyl-phenoxy)-phenyl]-methanol 在 三溴化磷 、 sodium hydride 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 4.5h， 生成 (6S)-2-nitro-6-({4-[4-(trifluoromethyl)phenoxy]benzyl}oxy)-6,7-dihydro-5Himidazo[2,1-b][1,3]oxazine
  参考文献：
  名称：

  Synthesis and Structure–Activity Relationships for Extended Side Chain Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  Novel extended side chain nitroimidazooxazine analogues featuring diverse linker groups between two aryl rings were studied as a potential strategy to improve solubility and oral activity against chronic infection by Mycobacterium tuberculosis. Both lipophilic and highly polar functionalities (e.g., carboxamide, alkylamine, piperazine, piperidine, but not sulfonamide) were well tolerated in vitro, and the hydrophilic linkers provided some solubility improvements, particularly in combination with pyridine rings. Most of the 18 compounds further assessed showed high microsomal stabilities, although in the acute infection mouse model, just one stilbene (6-fold) and two pyridine-containing acetylene derivatives (5-fold and >933-fold) gave in vivo efficacies notably superior to the clinical stage compound pretomanid (PA-824). The most efficacious analogue also displayed outstanding in vivo activity in the stringent chronic model (up to 24-fold better than the drug delamanid and 4-fold greater than our previous best phenylpyridine candidate), with favorable pharmacokinetics, including good oral bioavailability in the rat.

  DOI：

  10.1021/jm501608q
• 作为产物：
  描述：

  methyl 4-[4-(trifluoromethyl)phenoxy]benzoate 在 二异丁基氢化铝 、 水 、 Rochelle's salt 作用下， 以 四氢呋喃 、 正庚烷 、 甲醇 为溶剂， 反应 1.25h， 生成 [4-(4-trifluoromethyl-phenoxy)-phenyl]-methanol
  参考文献：
  名称：

  SOLUBLE GUANYLATE CYCLASE ACTIVATORS

  摘要：

  具有治疗或预防心血管疾病、内皮功能障碍、舒张功能障碍、动脉硬化、高血压、心绞痛、血栓形成、再狭窄、心肌梗死、中风、心脏衰竭、肺动脉高压、勃起功能障碍、支气管哮喘、慢性肾功能不全、糖尿病或人或动物患者肝硬化的化合物的结构。

  公开号：

  US20090209556A1

文献信息

• [EN] 2,6-DISUBSTITUTED PYRIDINES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS<br/>[FR] PYRIDINES 2,6-DISUBSTITUÉES COMME ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009071504A1

  公开（公告）日：2009-06-11

  Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, CF3, C1-4alkyl and allyl; Y represents (II), (III), (IV) or (V) wherein R3 represents CF3 or C1-4alkyl; and R3a represents CF3 or C1-4alkyl.

  公开的是式（I）的化合物，其中R1和R2分别选自氢、卤素、CF3、C1-4烷基和烯丙基；Y代表（II）、（III）、（IV）或（V），其中R3代表CF3或C1-4烷基；而R3a代表CF3或C1-4烷基。
• Discovery of Novel Cytochrome bc1 Complex Inhibitor Based on Natural Product Neopeltolide
  作者：Tao Chen、Rui Zhang、Yu-Xia Wang、Meng-Qi Gao、Qiong Chen、Xiao-Lei Zhu、Guang-Fu Yang

  DOI：10.2174/1570180818666211006142034

  日期：2022.4

  Natural products (NPs) are important sources for the design of new drugs and agrochemicals. Neopeltolide, a marine NP, has been identified as a potent Qo-site inhibitor of cytochrome bc1 complex.

  In this study, a series of neopeltolide derivatives was designed and synthesized by the simplification of its 14-membered macrolactone ring with a diphenyl ether fragment. The enzymatic inhibition bioassays and mycelium growth inhibition experiments against a range of fungi were performed to determine their fungicidal activities.

  The derivatives have potent activity against the porcine bc1 complex. Compound 8q showed the best activity with an IC50 value of 24.41 nM, which was 8-fold more effective than that of positive control azoxystrobin. Compound 8a exhibited a 100% inhibitory rate against Zymoseptoria tritici and Alternaria solani at a 20 mg/L dose.

  Computational results indicated that compounds with suitable physicochemical properties, as well as those forming a hydrogen bond with His161, would have good fungicidal activity. These data could be useful for the design of bc1 complex inhibitors in the future.

  背景：天然产物（NPs）是设计新药物和农药的重要来源。海洋天然产物新皮尔酮已被鉴定为细胞色素bc1复合物的有效Qo-位点抑制剂。 方法：本研究通过简化新皮尔酮14元大环内酯环并加入二苯醚基团，设计并合成了一系列新皮尔酮衍生物。采用酶抑制生物测定和对一系列真菌的菌丝生长抑制实验来确定它们的杀真菌活性。 结果：这些衍生物对猪bc1复合物具有强大的活性。化合物8q表现出最佳活性，其IC50值为24.41 nM，比阳性对照阿托霉素有效成分的效果高8倍。化合物8a在20 mg/L剂量下对小麦条锈菌和茄根黑斑病菌表现出100%的抑制率。 结论：计算结果表明，具有适当物理化学性质以及与His161形成氢键的化合物将具有良好的杀真菌活性。这些数据对未来设计bc1复合物抑制剂可能会有用。
• 4-OXY-N-[1,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR THERAPEUTIC USE
  申请人：KEIL Stefanie

  公开号：US20090012131A1

  公开（公告）日：2009-01-08

  The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, wherein the various unnamed substituents are defined herein. The compounds are suitable for the treatment of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及4-Oxy-N-[1,3,4]-噻二唑-2-基苯磺酰胺及其衍生物和盐，以及其制备方法和用作制药组合物的方法。更具体地，本发明涉及4-Oxy-N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理上功能性衍生物，其表现出过氧化物酶体增殖激活受体(PPAR) PPARalpha、PPARdelta和PPARgamma激动剂活性。这些化合物的结构由式I定义，其中各未命名的取代基在此定义。这些化合物适用于治疗脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗涉及的疾病，以及中枢和周围神经系统的脱髓鞘和其他神经退行性疾病的治疗。
• 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, pharmaceutical compositions and methods for their therapeutic use
  申请人：Sanofi-Aventis

  公开号：US07910612B2

  公开（公告）日：2011-03-22

  The present invention comprises 4-Oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, the derivatives thereof and salts thereof as well as processes for their preparation and methods for their use as pharmaceutical compositions. More specifically, the invention relates to 4-oxy-N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives that exhibit peroxisome proliferator activator receptor (PPAR) PPARalpha, PPARdelta and PPARgamma agonist activity. The compounds themselves are defined by the structure of the formula I, wherein the various unnamed substituents are defined herein. The compounds are suitable for the treatment of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

  本发明涉及4-氧基-N-[1,3,4]-噻二唑-2-基苯磺酰胺及其衍生物和盐，以及它们的制备方法和用作制药组合物的方法。更具体地，本发明涉及4-氧基-N-[1,3,4]-噻二唑-2-基苯磺酰胺及其生理上可接受的盐和生理上功能性衍生物，其表现出过氧化物酶体增殖物激活受体（PPAR）PPARalpha、PPARdelta和PPARgamma激动剂活性。这些化合物的结构由式I所示，其中各未命名的取代基在此定义。这些化合物适用于治疗脂肪酸代谢障碍和葡萄糖利用障碍，以及胰岛素抵抗涉及的疾病，以及中枢和外周神经系统的脱髓鞘和其他神经退行性疾病。
• WO2007/39171
  申请人：——

  公开号：——

  公开（公告）日：——